The present study was designed to investigate the hypolipidemic effect of ethanolic extract from whole plant of Lactuca runcinata (DC.) in rats fed with atherogenic diet (AD). The acute toxicity study shows that the ethanolic extract are safe up to 2000 mg/kg, thus one tenth of this dose was consider as evaluation dose. Ethanolic extract of Lactuca runcinata was administered in doses of 200 and 400 mg/kg/day to rats fed with atherogenic diet to assess its possible lipid-lowering potential. There was a recognize increment in the body weight in AD fed group (p<0.001), which was reduced by the administration of ethanolic extract of L. runcinata (400 mg/kg). The elevated levels of total cholesterol, triglycerides, phospholipids, low-density lipoprotein (LDL-C) and very low-density lipoprotein cholesterol (VLDL-C) all along with decrease in plasma HDL-C were observed in group II rats fed with atherogenic diet. After treatment of ethanolic extract of L. runcinata, (400 mg/kg/day) the result showed a significant (p<0.001) decrement in body weight, plasma and tissue total cholesterol, triglycerides, phospholipids, plasma LDL-C and VLDL-C although with an increase in plasma HDL-C when compared to group II AD rats. The ethanolic extract of L. runcinata could protect against atherosclerosis and decrease the atherogenic index and cardiac risk ratio. This finding provides some biochemical basis for the use of ethanolic extract of whole plant of L. runcinata as hypolipidemic agent having preventive and therapeutic effect against hyperlipidemia.
INTRODUCTION
Hyperlipidemia is a known risk factor for the advancement of cardiovascular diseases including atherosclerosis. The real risk components for the advancement of atherosclerosis are hypercholesterolemia and raised levels of low-density lipoprotein cholesterol (LDL-C). Moreover, free-radical-mediated peroxidative modification of polyunsaturated fatty acids of LDL and very lowdensity lipoprotein (VLDL) is thought to add to the development of atherosclerotic injuries. Oxidative anxiety is an early occasion in the advancement of hyperlipidemia, and it has been proposed that proper support for improving antioxidant supply in subjects with anomalous elevated lipid levels can lessen the course of the disease (Yang et al., 2008) .
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Clinical trials have demonstrated that treatment of more seasoned high-risk subjects with lipid-lowering medications can lessen cardiovascular grimness and mortality (Aronow, 2008) . The investigation for new agents fit for diminishing serum lipid levels has thusly turn into a vital examination center.
Plant items are by and large thought to be less harmful and less inclined to reactions than medications made by synthetic compounds. The potential therapeutic and preventive benefits of plant-based drugs have been the subject of broad studies, and numerous plant constituents have been revealed with significant pharmacologic activity (Kumari and Augusti, 2007; Son et al., 2007) incorporating agents with antiglycemic, hypolipidemic and antihypertensive properties (Lactuca runcinata DC; Synonyms, Lactuca heyneana DC.. Family: Compositae; Asteraceae). This occurs in many parts of India, as a common weed. It is considered as a valuable medicinal herb in traditional systems of medicine in India (Action diuretic, slightly aperients). It is used as a diuretic in calculous affections, also for chronic obstruction of liver and bowels (Khare, 2008) . A smaller variance found in western Uttar Pradesh, Rajasthan, Saurashtra and the Deccan Penninsula, is equated with Lactuca remotiflora DC. However, the plant is reported to possess the activities like antibacterial activity in methanolic extract (Lakshmi et al., 2013) , and in vitro cytotoxic activity in methanolic extract (Lakshmi et al., 2014) . Literature survey revealed that there is no earlier scientific reports regarding hypolipidemic activity of this plant. Therefore, objective of the present investigation was to study the effect of ethanolic extract of whole plant of Lactuca runcinata (DC.) on hyperlipidemia elicited by atherogenic diet in rats.
MATERIALS AND METHODS

Plant materials
The fresh whole plants of L. runcinata DC were collected from the natural habitats of Kayathar, Thoothukkudi district, Tamil Nadu, India. Taxonomic distinguishing proof was produced using Botanical Survey of Medical Plants Unit Siddha, Government of India, Palayamkottai. The samples were washed thoroughly in running tap water to remove soil particles and adhered debris and finally washed with sterile distilled water. The whole plants were shade dried and ground into fine powder. The powdered materials were stored in air tight polythene bags until use.
Chemicals
Atorvastatin free sample was received from Ranbaxy Laboratories Limited, Gurgaon, India. All other chemicals and solvents were analytical grade used in the experiments were purchased locally (Merck or SD fine Chemicals).
Preparation of extract
The earlier mentioned powdered materials were successively Devi and Muthu 1081 extracted with ethanol (40 to 60°C) by hot continuous percolation method in Soxhlet apparatus (Harborne, 1984) for 24 h. Then the extract was concentrated by using a rotary evaporator and subjected to freeze drying in a lyophilizer till dry powder was obtained. 
Animals
Animal diet
The compositions of the two diets were used as follows (Kottai et al., 2005) : 
Acute toxicity studies
Oral acute toxicity studies were carried out with male wistar rats weighing 150 to 180 g as per (OECD) draft guidelines rules 423 adopted on 17 December, 2001 gotten from Committee for the purpose of Control and Supervision of Experimental Animals (CPCSEA). The rats were fed with ethanolic extract of L. runcinata suspended in 1% gum acacia at the dose of 2000 mg/kg body weight. The animals were observed independently at regular intervals subsequent to dosing the initial 24 h and from that point every day for an aggregate of 14 days. The time at which indications of toxicity appear and disappear was observed methodically and recorded for every animal.
Experimental design
A total number of 30 rats were divided into five groups of six rats each: The ethanolic extract and atorvastatin were suspended in 2% tween 80 (Waynforth, 1980) individually and fed to the relevant rats by oral intubation. In the ethanolic extract at the dosage level of 200 and 400 mg/kg were fixed as per the Organisation for Economic Cooperation and Development (OECD) guidelines. At the end of 9 weeks, after overnight fasting all the rats were sacrificed by cervical dislocation. Just before sacrifice, blood was collected from the retroorbital sinus plexus under mild ether anesthesia and blood sample withdrawn in heparinised tubes and plasma was separated. Liver, heart and aorta were cleared of adhering fat, estimated accurately and utilized for the preparation of homogenate. Animals were given enough care as per the Animal Ethical Committee's recommendations.
Biochemical analysis
Plasma samples were estimated for total cholesterol, HDLcholesterol and triglycerides utilizing Boehringer Mannheim kits by Erba Smart Lab analyzer United States of America. Friedwald method (Freidewald et al., 1972) was used to determine the LDLcholesterol and VLDL-cholesterol. Ester cholesterol (Sperry and Webb, 1950) and free cholesterol (Sperry and Webb, 1950) were estimated by utilizing digitonin. Segments of liver tissues, heart tissues and aorta tissues were blotted, measured and homogenized with 3 volumes of methanol and the lipid extracts were gotten by the method (Folch et al., 1957) . Extract was utilized for the estimation of ester cholesterol and free cholesterol, triglycerides (Foster and Dunn, 1973) , and phospholipids (Zilversmit and Davis, 1950) . Free fatty acids were estimated by using method (Falholt et al., 1973) . Plasma total cholesterol: HDL-cholesterol ratio and LDLcholesterol: HDL-cholesterol ratio was also calculated to access the atherogenic risk (Li et al., 2013) , cardiac risk ratio (Huang et al., 2013) and Atherogenic coefficient (Mizuno et al., 2012) .
Statistical analysis
The results were expressed as mean ± standard deviation of 6 rats in each group. The statistical significance between the groups was carried out by using one way ANOVA as in standard statistical software package of social science (SPSS).
RESULTS
From the acute toxicity, it was found that the ethanolic extracts are safe up to 2000 mg/kg thus one tenth of this dosage (200mg/kg) was considered as the assessment dose. Table 1 shows the body weight of group II rats increased significantly (p<0.001) in comparison with normal control group I rats. The increment in the weight was reduced considerably (p<0.001) by the administration of ethanolic extract of L. runcinata (400 mg/kg), and standard drug atorvastatin 1.2mg/kg in comparison with the group II AD fed rats. The average food intake per rat per day was found to be 20.5±1.0 g. Food intake was the same in all the AD rats. Table 2 reveals that there was a significant increase (p<0.001) in the level of plasma total cholesterol, ester cholesterol, free cholesterol, free fatty acid, phospholipids and triglycerides in the group II rats fed with AD in comparison with the normal untreated control rats (Group I). Treatment with ethanolic extract of L. runcinata at the dose 200 mg/kg body weight was found significantly reduced (p<0.001) in the level of plasma total cholesterol, ester cholesterol, free cholesterol, free fatty acid phospholipids and triglycerides in comparison with AD rats (group II). However, group IV (ethanolic extract of Lactuca runcinata with AD) showed that the plasma total cholesterol, ester cholesterol, free cholesterol, free fatty acid phospholipids and triglycerides level was restored to near normal as that of group V (atorvastatin 1.2mg/kg with AD). Table 3 demonstrates in the AD group a significant increase in the value of atherogenic index of 4.39± 0.04 (p<0.001), while the group receiving ethanolic extract of L. runcinata along with atherogenic diet, showed a significant decrease in atherogenic index 1.86±0.03 (p<0.001), comparable to the normal control group 1.97±0.02 (p<0.001). Table 4 reveals the reduction in the HDL produced by the group of animals fed with AD was significant (p<0.001) in comparison with group I animals. However, the treatment with ethanolic extract of L. runcinata at the dose of 400 mg/kg considerably increased the HDL-cholesterol level when compared to group II atherogenic diet rats. The increased levels of LDL and VLDL-cholesterol in group II rats fed with atherogenic diet was significant (p<0.001) in comparison with group I control rats. Treating with ethanolic extract of L. runcinata (Group IV) showed noticeably reduction in the level of plasma LDL-cholesterol and VLDL-cholesterol when compared to group II AD rats.In comparison of the two dose of extract group (Group III and IV) with group II AD rats, the ethanolic extract of L. Runcinata at the dosage of 400 mg/kg was revealed noteworthy reduction on both LDL-cholesterol and VLDLcholesterol.
Groups
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Group
The atherogenic diet rats caused significant (p<0.001) increase in the ratios of total cholesterol: HDL-cholesterol and LDL-cholesterol: HDLcholesterol. A significant (p<0.001) increase in the ratios of total cholesterol: HDL-cholesterol and LDL-cholesterol: HDL-cholesterol in the group II rats fed with AD in comparison with normal group I untreated rats. Administration of ethanolic extract of L. runcinata along with AD significantly reduced the ratios of total cholesterol: HDL-cholesterol and LDL-cholesterol: HDL-cholesterol when compared to AD group (II). Tables 5 and 6 shows the considerable (p<0.001) raise in levels of both free cholesterol and ester cholesterol, this were also observed in tissue of group II rats fed atherogenic diet when compared to group I control rats. On treating the atherogenic diet rats with ethanolic extract of L. runcinata at the dosage of 400 mg/kg, both the tissues cholesterol like ester and free cholesterol reduced remarkably. Table 7 demonstrates the concentration of tissue triglyceride was elevated in rats fed with group II atherogenic diet rats as compared to group I control rats. The tissue triglyceride levels were considerably decreased in rats treated with ethanolic extracts of Lactuca runcinata at the dosage of 200 and 400 mg/kg and along standard drug atorvastatin all along with AD when compared with group II rats fed with atherogenic diet. Administration of ethanolic extract of Lactuca runcinata significantly reduced the triglyceride. Table 8 illustrates the concentration tissue phospholipids which were significantly increased in group II rats fed with AD as compared to group I control animals. Treating with ethanolic extract of L. runcinata along with AD showed reduced the phospholipids levels when compared to group II AD fed rats.
Administration of ethanolic extract of L. runcinata significantly (p<0.001) reduced the phospholipids level. Values are expressed as mean±SE (n=6 rats), P values: * < 0.001, ** < 0.05,NS: Non significant, a→group I compared with groups II, III, IV, V; b→group II compared with groups III, IV, V. Table 6 . Effect on tissues free cholesterol profile by using ethanolic extract of L. runcinata in control and experimental wistar rats.
Groups
Free 
DISCUSSION
The reduction of the plasma lipid and lipoprotein profile was due to the presence of total phenolic and flavonoids compounds. Atorvastatin has more side effects like headache, hoarseness, lower back or side pain, loss of appetite, heartburn and indigestion etc. So the study has selected herbal extract for medicine without any side effect compared with synthetic drugs. These days, hyperlipidemia, particularly hypercholesterolemia is related with a danger for the occurrence of coronary heart disease and fatty liver (Yadav et al., 2012) . Numerous new synthetic oral antihyperlipidemic medications, for example, fibrates and bile acid sequestrants are accessible yet they have many adverse reactions, for example, myopathy, increment in hepatic amino transferases and rhabdomyolysis condition (Porez et al., 2012; Saito, 2012) . Recently, numerous research work have concentrated on the therapeutic capability of plant constituents for treating numerous vital common diseases, particularly obesity and its complications (Heidarian et al., 2011a; Andersen et al., 2010; Heidarian et al., 2011b) .
Plasma lipid profiles are elevated in the group receiving atherogenic diet; earlier studies reveal significant elevation of lipid parameters in plasma and tissue response to atherogenic diet or high fat diet (Prasad, 2005; Vijaimohan et al., 2006; Mehta et al., 2003) . The reduction in the HDL produced by the group of animals fed with HFD, is highly significant in that low HDLcholesterol is now considered as the most significant risk factor for atherosclerosis (Gordon and Rifkind, 1989; Brewer, 2004) . After administration of ethanolic extract of L. runcinata showed significantly increased HDL-C concentration. It is well known that increased HDLcholesterol levels have a protective role in coronary artery disease (Wilson et al., 1988) . HDL may be protective by reversing cholesterol transport, inhibiting the oxidation of LDL and by neutralizing the atherogenic effects of oxidized LDL (Parthasarathy et al., 1990) .
The elevated levels of LDL and VLDL-cholesterol in rats fed with HFD, clinical and epidemiological studies have proved that individuals with elevated LDL show an increased risk for cardiovascular diseases (Keevil et al., 2007) . Supplementation of cholesterol in diet rapidly results in a marked increase in the production of cholesteryl rich-VLDL by the liver and intestine (Damacker et al., 1991) and a reduced number as well as rate of cholesterol removal by the hepatic LDL receptors (Goldstein et al., 1983) . In this study, the intake of the atherogenic or lipogenic diet led to the increase of the plasma levels of cholesterol, VLDL, LDL in group II (hyperlipidemic animals) while, in groups III and IV (rats treated with crude extract) the plasma levels of cholesterol, VLDL, LDL, significantly decreased compared to groups I and II, respectively. The level of LDL-C and VLDL-C were significantly reduced by administration of ethanolic extract of L. runcinata can be helpful to reduce the risk of atherosclerosis, cardiovascular diseases and fatty liver. There is strong evidence from several studies that the extent of reduction in the incidence of CHD is directly related to the magnitude of reduction in LDLc and VLDLc levels (Pekkanen et al., 1990) .
The atherogenic diet rats significantly increased in the ratios of total cholesterol: HDL-cholesterol and LDLcholesterol: HDL-cholesterol. A significant increased in the ratios of total cholesterol: HDL-cholesterol and LDLcholesterol: HDL-cholesterol indicate increased risk of atherosclerosis and coronary heart disease (Ram, 1996) . Decline in the ratios of total cholesterol: HDL-cholesterol and LDL-cholesterol: HDL-cholesterol observed in the ethanolic extract of L. runcinata treated rats (group IV) might be consequence of higher proportion of HDLcholesterol which reduced risk by virtue of increased reverse cholesterol transport from peripheral organs to liver (Kinosian et al., 1994; Hermansen et al., 2003) .
The ester and free cholesterol levels were significantly increased in AD group (II) in comparison with control rats. This high cholesterol concentration in blood circulation may injure the endothelial cells lining the large arteries and aorta, and this might be an initial event in the etiology of atherosclerosis (Hennig and Chow, 1998) . Treatment with ethanolic extract of L. runcinata reduces the level of both ester and free cholesterol. This lipid lowering outcome may be due to the inhibition of hepatic cholesterogenesis or due to the increase in excretion of fecal sterol (Purohit and Vyas, 2006) .
The concentration of plasma and tissue triglyceride was elevated in rats fed with atherogenic diet. Recent studies also show that triglycerides are independently related to coronary heart disease (Bainton et al., 1992; El-Hazmi and Warsy, 2001 ) and most of the antihypercholesterolemic drugs do not decrease triglycerides levels, but ethanolic extract of L. runcinata lowered it significantly (p<0.001) and this effect might be related to increase the endothelium bound lipoprotein lipase which hydrolyses the triglycerides into fatty acids. The concentration of plasma and tissue phospholipids were significantly increased in rats fed with AD, this may be due to decreased phospholipase activity (Mirhadi and Sudarshan Singh, 1991; Whereat and Robinowitz, 1975) . The group receiving ethanolic extract of L. runcinata significantly (p<0.001) reduced the phospholipids. The plant extract may have stimulation of lipoprotein lipase activities resulting in decrease of plasma triglyceride and might increase the uptake of triglyceride from plasma by skeletal muscle and adipose tissues (El-Hazmi and Warsy, 2001 ).
CONCLUSION
The result of present study revealed that the ethanolic extract of whole plant of L. runcinata significantly reduced the plasma lipid and lipoprotein profile, thus reduced the atherogenic index and cardiac risk ratio. It also significantly reduced the tissues free cholesterol, ester cholesterol, triglycerides and phospholipids. This finding provides some biochemical basis for the use of ethanolic extract of whole plant of L. runcinata as antihyperlipidemic agent having preventive and curative effect against hyperlipidemia. This study plan to lead further studies is required to again more insight into the possible mechanism of action of this medicinal plant.
